Search
Tinidazole
go.drugbank.com/drugs/DB00911ApprovedInvestigationalA nitroimidazole antitrichomonal agent effective against Trichomonas vaginalis, Entamoeba histolytica, and Giardia lamblia infections.
Omalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigational[A39518] Omalizumab was first approved in the US in 2003 [A263507] and in Europe in 2005. … By binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its receptors on immune cells.
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).
Mangafodipir
go.drugbank.com/drugs/DB06796ApprovedInvestigationalWithdrawnThis drug is made up of paramagnetic manganese (II) ions combined with the chelating agent _fodipir_ (dipyridoxyl diphosphate, DPDP). … Teslascan has been removed from the Drug Product List by FDA in 2003, and withdrawn from the European market in 2012.
Brincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalIt is a lipid conjugate pro-drug of the acyclic nucleotide analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity … Brincidofovir, developed by Chimerix under the brand name Tembexa, was approved by the FDA for the treatment of smallpox infection in June 2021.
Pentoxifylline
go.drugbank.com/drugs/DB00806ApprovedInvestigational[A226608] Pentoxifylline has been marketed in Europe since 1972; PTX extended-release tablets sold under the trade name TRENTAL by US Pharm Holdings were first approved by the FDA on Aug 30, 1984, but … A branded product, PENTOXIL, marketed by Upsher-Smith Laboratories, and generic forms marketed by Valeant Pharmaceuticals and APOTEX have been available since the late 1990s.[L30300]
Sotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed … [L39705] Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors
Ginsenoside Rd
go.drugbank.com/drugs/DB19256InvestigationalGinsenoside Rd is under investigation in clinical trial NCT00815763 (Efficacy and Safety of Ginsenoside-rd for Acute Ischemic Stroke).
Categories: PanaxDeflazacort
go.drugbank.com/drugs/DB11921ApprovedIt is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. … [A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7.
Chlorthalidone
go.drugbank.com/drugs/DB00310ApprovedInvestigationalChlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. … Chlorthalidone improves blood pressure and swelling by preventing water absorption from the kidneys through inhibition of the Na+/Cl− symporter in the distal convoluted tubule cells in the kidney.